{"preliminary_commentary":{"by_channel":{"x_thread":5},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"NCT03571321","nct_id":"NCT03571321","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct03571321. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants will receive ruxolitinib in addition to standard chemotherapy.\n\nStandard Chemotherapy Consists of:\n\n* Remission consolidation therapy (lasting 8 weeks)\n* Interim Maintenance (lasting 8 weeks)\n* Delayed Intensification (lasting 8 weeks\n* Maintenance Therapy (12 week courses/84 day cycles lasting 2-3 years)\n\nPrior to study entry, patients must have completed a 4-drug induction therapy regimen with intrathecal chemotherapy (modified Berlin-Frankfurt-Münster (aBFM) regimen or equivalent) as per the institution standard of care.","label":"Ruxolitinib","type":"EXPERIMENTAL"}],"collaborators":["Incyte Corporation"],"completion_date":{"date":"2027-09-05","type":"ESTIMATED"},"conditions":["Acute Lymphoblastic Leukemia","ALL, Childhood","ALL"],"enrollment":{"count":15,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Ruxolitinib","otherNames":["Jakafi"],"type":"DRUG"},{"name":"Cyclophosphamide","otherNames":[],"type":"DRUG"},{"name":"Cytarabine","otherNames":[],"type":"DRUG"},{"name":"Mercaptopurine","otherNames":[],"type":"DRUG"},{"name":"Vincristine","otherNames":[],"type":"DRUG"},{"name":"Pegaspargase","otherNames":[],"type":"DRUG"},{"name":"Rituximab","otherNames":[],"type":"DRUG"},{"name":"Methotrexate (Intrathecal Administration)","otherNames":[],"type":"DRUG"},{"name":"Methotrexate (Intravenous Administration)","otherNames":[],"type":"DRUG"},{"name":"Dexamethasone","otherNames":[],"type":"DRUG"},{"name":"Doxorubicin","otherNames":[],"type":"DRUG"},{"name":"Thioguanine","otherNames":[],"type":"DRUG"},{"name":"Methotrexate Oral Product","otherNames":[],"type":"DRUG"}],"last_update":"2026-06-29","lead_sponsor":"University of Chicago","official_title":"Phase I Trial of Ruxolitinib in Combination With a Pediatric Based-regimen for Adolescents and Young Adults (AYAs) With Ph-like Acute Lymphoblastic Leukemia (ALL)","overall_status":"RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2026-09-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Feasibility of adding ruxolitinib to a standard-of-care pediatric-based chemotherapy regimen in adolescents and young adult patients as determined by rate of side effects seen when combination is given","timeFrame":"24 weeks"}],"references":[],"start_date":{"date":"2019-05-28","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia","url":"https://clinicaltrials.gov/study/NCT03571321"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct03571321"}